Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Jairam

Physician Assistant Long Beach, CA Physician Assistant

NPI 1154806487 CMS profile 11058850

1045 Atlantic Ave Ste 719, Long Beach, CA 90813

Open in the dashboard

General payments

$23,751

1,264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Jairam of Long Beach, CA is reported in the CMS Open Payments database as having received $23,751 across 1,264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,194 141
2024 General $5,347 254
2023 General $4,119 240
2022 General $5,184 294
2021 General $5,907 335

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Jairam
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Jairam were reported at $3,194. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Jairam Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $5,907 $132 $37–$438 $132
2022 $5,184 $155 $48–$522 $149
2023 $4,119 $167 $52–$557 $160
2024 $5,347 $178 $55–$600 $164
2025 $3,194 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,178 239 payments
  2. UCB, Inc. $2,341 107 payments
  3. Teva Pharmaceuticals USA, Inc. $1,425 86 payments
  4. Biogen, Inc. $1,214 57 payments
  5. Lundbeck LLC $1,094 43 payments
  6. Neurelis, Inc. $958 60 payments
  7. Novartis Pharmaceuticals Corporation $849 74 payments
  8. Biohaven Pharmaceuticals, Inc. $841 30 payments
  9. Amgen Inc. $800 51 payments
  10. Boston Scientific Corporation $774 12 payments
  11. Other $10,276 505 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,262 1,258 payments
  2. Education $489 6 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $2,304 175 payments
  2. NURTEC ODT $1,452 67 payments
  3. QULIPTA $1,139 93 payments
  4. VALTOCO $958 60 payments
  5. Briviact $885 40 payments
  6. AIMOVIG $835 54 payments
  7. VYEPTI $802 30 payments
  8. INGREZZA $654 26 payments
  9. Zilbrysq $649 32 payments
  10. VUMERITY $625 28 payments
  11. Other $14,385 767 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

1,924

Median for Physician Assistant: 241

Drug cost

$1,264,723

Median for Physician Assistant: $4,110

Branded share of claims

34.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $314,167
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 11 $261,548
Austedo Deutetrabenazine Brand 12 $122,897
Emgality Pen Galcanezumab-Gnlm Brand 137 $112,028
Kesimpta Pen Ofatumumab Brand 12 $97,625
Qulipta Atogepant Brand 64 $95,560
Aimovig Autoinjector Erenumab-Aooe Brand 64 $58,590
Oxtellar Xr Oxcarbazepine Brand 26 $50,659
Ubrelvy Ubrogepant Brand 26 $40,940
Nurtec Odt Rimegepant Sulfate Brand 28 $40,055

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 51 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilbrysq
$385 — —
UBRELVY
$365 26 —
VYEPTI
$303 — —
Briviact
$295 — —
VALTOCO
$250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 51 with Patron

Records

1,264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record